We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 33% above its sector, the market expects faster growth.
Shandong Wohua Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, production, and distribution of a broad array of medicinal products across the country. The company's extensive product portfolio addresses various therapeutic categories. Key offerings include Xinkeshu tablets, Naoxueshu oral solutions, and Tongluo Huayu capsules, which are specifically formulated for cardiovascular and cerebrovascular health. Beyond these, Shandong Wohua also supplies medications for respiratory conditions, drugs targeting the urinary and digestive systems, anti-rheumatic treatments, and sedative agents. Furthermore, it provides specialized pharmaceuticals tailored for women and children. Headquartered in Weifang, China, the company operates as a subsidiary under the ownership of Beijing Zhongzheng Wanrong Investment (Group) Co., Ltd.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 002107.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
